Abstract
The mammalian target of rapamycin (mTOR) kinase is positioned at the juncture of several pathways regulating cell growth and proliferation. It is the downstream effector of the oncogenic PI3K/Akt pathway and is a key regulator of translational initiation. Accumulating data support mTORs role in lymphomagenesis, and its inhibition in preclinical models leads to lymphoma regression. The rationale for testing mTOR inhibitors in patients with lymphoma is evident, and early clinical data is promising. Along with the prototype of mTOR inhibitors, rapamycin, there are three mTOR inhibitors furthest along in development: temsirolimus, everolimus, and AP23573. These agents are emerging as well-tolerated drugs with encouraging preliminary activity. Here we review the rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing dose and schedule of mTOR inhibitors, and summarize the clinical results in obtained to date in patients with lymphoma.
Keywords: mTOR, mTOR inhibitors, non-Hodgkin lymphoma, rapamycin, clinical trials, pharmacokinetics
Reviews on Recent Clinical Trials
Title: Clinical Development of mTOR Inhibitors: A Focus on Lymphoma
Volume: 2 Issue: 2
Author(s): Sonali M. Smith
Affiliation:
Keywords: mTOR, mTOR inhibitors, non-Hodgkin lymphoma, rapamycin, clinical trials, pharmacokinetics
Abstract: The mammalian target of rapamycin (mTOR) kinase is positioned at the juncture of several pathways regulating cell growth and proliferation. It is the downstream effector of the oncogenic PI3K/Akt pathway and is a key regulator of translational initiation. Accumulating data support mTORs role in lymphomagenesis, and its inhibition in preclinical models leads to lymphoma regression. The rationale for testing mTOR inhibitors in patients with lymphoma is evident, and early clinical data is promising. Along with the prototype of mTOR inhibitors, rapamycin, there are three mTOR inhibitors furthest along in development: temsirolimus, everolimus, and AP23573. These agents are emerging as well-tolerated drugs with encouraging preliminary activity. Here we review the rationale for testing mTOR inhibitors in lymphoma, the phase 1 trials influencing dose and schedule of mTOR inhibitors, and summarize the clinical results in obtained to date in patients with lymphoma.
Export Options
About this article
Cite this article as:
Smith M. Sonali, Clinical Development of mTOR Inhibitors: A Focus on Lymphoma, Reviews on Recent Clinical Trials 2007; 2 (2) . https://dx.doi.org/10.2174/157488707780599366
DOI https://dx.doi.org/10.2174/157488707780599366 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Recent Development in Indole Derivatives as Anticancer Agent: A Mechanistic Approach
Anti-Cancer Agents in Medicinal Chemistry Radioimmunotherapy of Cancer Using Monoclonal Antibodies to Target Radiotherapy
Current Pharmaceutical Design Pathologic Findings of Autoimmune Pancreatitis and IgG4-Related Disease
Current Immunology Reviews (Discontinued) Advances in Peptide Pharmaceuticals
Current Pharmaceutical Biotechnology Par-4 for Molecular Therapy of Prostate Cancer
Current Drug Targets Kit: Molecule of Interest for the Diagnosis and Treatment of Mastocytosis and other Neoplastic Disorders
Current Cancer Drug Targets Ultrasound-Triggered Immunotherapy for Cancer Treatment: An Update
Current Protein & Peptide Science Farnesyltransferase Inhibitors and Rapamycin in the Treatment of Multiple Myeloma
Current Pharmaceutical Biotechnology Bioactive Sterol Derivatives Isolated from the <i>Pleurotus djamor</i> var. Roseus Induced Apoptosis in Cancer Cell Lines
Cardiovascular & Hematological Agents in Medicinal Chemistry Internal Ribosome Entry Site Elements in Eukaryotic Genomes
Current Genomics Relevance of Breast Cancer Resistance Protein to Brain Distribution and Central Acting Drugs: A Pharmacokinetic Perspective
Current Drug Metabolism Meet Our Editorial Board Member:
Protein & Peptide Letters Novel Antigen Targets for Immunotherapy of Acute Myeloid Leukemia
Current Drug Targets Polypharmacology of <i>Aconitum</i> and <i>Delphinium</i> sp. Diterpene Alka loids: Antiarrhythmic, Analgesic and Anti-Inflammatory Effects
Mini-Reviews in Organic Chemistry An Evidence-Based Review of the Mechanism of Action, Efficacy, and Safety of Biologic Therapies in the Treatment of Psoriasis and Psoriatic Arthritis
Current Medicinal Chemistry Histone Deacetylases: Anti-Angiogenic Targets in Cancer Therapy
Current Cancer Drug Targets Targeting the Folate Receptor: Effects of Conjugating Folic Acid to DOX Loaded Polymeric Micelles
Anti-Cancer Agents in Medicinal Chemistry Tyrosine Kinases as Molecular Targets to Inhibit Cancer Progression and Metastasis
Current Pharmaceutical Design Focused Microarray Analysis: Characterization of Phenomes by Gene Expression Profiling
Current Pharmacogenomics Therapeutic Polycomb Targeting in Human Cancer
Recent Patents on Regenerative Medicine